Summit Trail Advisors’s Lisata Therapeutics LSTA Stock Holding History

Summit Trail Advisors’s Portfolio LSTA Stock Details LSTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,182	Closed	-$9K	–	404
2022 Q2	$9K	Hold	1,182	–	–	﹤0.01%	383
2022 Q1	$13K	Hold	1,182	–	–	﹤0.01%	327
2021 Q4	$15K	Hold	1,182	–	–	﹤0.01%	297
2021 Q3	$22K	Hold	1,182	–	–	﹤0.01%	264
2021 Q2	$29K	Hold	1,182	–	–	﹤0.01%	221
2021 Q1	$34K	Hold	1,182	–	–	﹤0.01%	193
2020 Q4	$25K	Hold	1,182	–	–	﹤0.01%	185
2020 Q3	$27K	Hold	1,182	–	–	0.01%	210
2020 Q2	$32K	Hold	1,182	–	–	0.01%	165
2020 Q1	$32K	Buy	+1,182	New	+$45.8K	0.01%	123
2019 Q4	–	Sell	-1,182	Closed	-$46K	–	99
2019 Q3	$46K	Buy	+1,182	New	+$45.9K	0.02%	89
2019 Q2	–	Sell	-1,182	Closed	-$64K	–	81
2019 Q1	$64K	Buy	+1,182	New	+$77.7K	0.03%	82
2018 Q2	–	Sell	-1,182	Closed	-$73K	–	579
2018 Q1	$73K	Hold	1,182	–	–	0.01%	404
2017 Q4	$76K	Buy	+1,182	New	+$59.4K	0.01%	707

Other funds holding LSTA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Cook Wealth Raleigh, North Carolina $206M AUM 4.73% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Summit Trail Advisors's LSTA Position: Q3 2022 in Review

Summit Trail Advisors sold out of Lisata Therapeutics (LSTA) in Q3 2022, closing a stake of 1,182 shares — an estimated $9K sold.

Summit Trail Advisors first reported a position in LSTA in Q4 2017 and held it in 14 quarters. The position peaked at $76K in Q4 2017. 22 funds tracked by Wall St. Rank hold LSTA as of Q3 2022.

Summit Trail Advisors reported no remaining Lisata Therapeutics position as of Q3 2022 after selling out during the quarter.
Summit Trail Advisors sold 1,182 Lisata Therapeutics shares in Q3 2022, an estimated $9K.
Summit Trail Advisors first reported a position in Lisata Therapeutics in Q4 2017 and held it in 14 quarters.
Summit Trail Advisors's Lisata Therapeutics position peaked at $76K in Q4 2017.
22 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q3 2022.

Based on Summit Trail Advisors's 13F filing for Q3 2022, filed 10 Nov 2022.